In this vein, administration of an anti-tau antibody to tau transgenic mice and patients with progressive supranuclear palsy, a tau-related neurodegenerative disorder, resulted in a dose-dependent increase in plasma tau that was bound to antibody, and correlated with the concentration of extracellular and soluble tau in the brain [38, 91]. This evidence concerns the gene MAPT and progressive supranuclear palsy.